Cited by 1,557Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Open access

Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto, Antonio M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200106283442601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200106283442601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citation
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952

Show all 27 references

Sorted by citations

Items 801–900 of 998

Statins: the next anti-endotoxin
Krüger, P. (2006) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)02094-x · Cited by 23
C-reactive protein as a novel biomarker
Elgharib, N. Z., Chi, D. S., Younis, W. G., Wehbe, S. A., & Krishnaswamy, G. A. (2003) · Postgraduate Medicine · doi:10.3810/pgm.2003.12.1547 · Cited by 23
Is there a need for novel cardiovascular risk factors?
von Eckardstein, A. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh111 · Cited by 24
Statins: potent vascular anti-inflammatory agents
Liao, J. K. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00375.x · Cited by 23
The Predictive Value of C-Reactive Protein in End-Stage Renal Disease: Is It Clinically Significant?
SANDE, F. M. V. D., Kooman, J. P., & Leunissen, K. M. L. (2006) · Blood Purification · doi:10.1159/000092279 · Cited by 22
Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism
Srivastava, R. A. K., Cornicelli, J. A., Markham, B. E., & Bisgaier, C. L. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3353-5 · Cited by 22
Comparing HMG-CoA reductase inhibitors
Jones, P. H. (2003) · Clinical Cardiology · doi:10.1002/clc.4960261306 · Cited by 23
Use of Statins and Aspirin to Reduce Risks of Cardiovascular Disease
Hebert, P. R., Pfeffer, M. A., & Hennekens, C. H. (2002) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840200700203 · Cited by 22
AMPK activation may suppress hepatic production of C-reactive protein by stimulating nitric oxide synthase
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.01.044 · Cited by 22
C‐Reactive Protein, Statins, and the Primary Prevention of Atherosclerotic Cardiovascular Disease
Bermudez, E. A., & Ridker, P. M. (2002) · Preventive Cardiology · doi:10.1111/j.1520-037x.2002.1032.x · Cited by 22
Self-citation
Activation of the complement system: a crucial link between inflammation and atherosclerosis?
Kostner, K. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01431.x · Cited by 22
Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]
Ošťádal, P., Alan, D., Hájek, P., Vejvoda, J., Mates, M., Blaško, P., Veselka, J., Kvapil, M., Kettner, J., Wiendl, M., et al. (2005) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-6-4 · Cited by 22
The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II
Armani, A. M., & Becker, R. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.12.032 · Cited by 22
Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?
Lorenzatti, A. J., & Retzlaff, B. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.061 · Cited by 23
Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis
Borghi, C., & Levy, B. I. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.11.015 · Cited by 20
A bidirectional Mendelian randomized study of classical blood lipids and venous thrombosis
Lin, L., Luo, P., Yang, M., Wang, J., Hou, W., & Xu, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-31067-z · Cited by 21
Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report
Schnell‐Inderst, P., Schwarzer, R., Göhler, A., Grandi, N. C., Grabein, K., Stollenwerk, B., Manne‐Goehler, J., Klauß, V., Siebert, U., & Wasem, J. (2010) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462309990870 · Cited by 21
Reduction of risk factors for cardiovascular diseases in African Americans with a 12-week nutrition education program
Qian, J., Wang, B., Dawkins, N. L., Gray, A. L., & Pace, R. D. (2007) · Nutrition Research · doi:10.1016/j.nutres.2007.03.005 · Cited by 21
Novel non‐invasive approach for visualizing inflamed atherosclerotic plaques using fluorodeoxyglucose‐positron emission tomography
Kai, H. (2009) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2009.00564.x · Cited by 21
Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice.
Zebrack, J., & Anderson, J. L. (2002) · Progress in Cardiovascular Nursing · doi:10.1111/j.0889-7204.2002.1118.x · Cited by 28
Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease
Fichtlscherer, S., Kaszkin, M., Breuer, S., Dimmeler, S., & Zeiher, A. M. (2004) · Clinical Science · doi:10.1042/cs20030399 · Cited by 21
Avaliação de dislipidemia e de índices antropométricos em pacientes com Diabetes Mellitus tipo 1
Arcanjo, C. L., Piccirillo, L. J., Machado, I. D. V., de Andrade, C. R. M., Clemente, E. L. S., & Gomes, M. B. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000600015 · Cited by 21
Effect of Statin Therapy Before Q-Wave Myocardial Infarction on Myocardial Perfusion
Hoffmann, R., Haager, P. K., Suliman, H., Christott, P., Radke, P. W., Blindt, R., & Kelm, M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.059 · Cited by 21
The effect of infections and vaccinations on stroke risk
Grau, A. J., Marquardt, L., & Lichy, C. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.2.175 · Cited by 21
Pleiotropic effects of statins: Moving beyond cholesterol control
Garcia, P. J. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0073-6 · Cited by 20
Novel serologic markers of cardiovascular risk
Oliveira, G. H. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0038-9 · Cited by 21
Statins and inflammatory markers
Case, C. C., & Ballantyne, C. M. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0061-z · Cited by 21
Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment
Bunch, T. J., Muhlestein, J. B., Anderson, J. L., Horne, B. D., Bair, T. L., Jackson, J. D., Li, Q., & LAPPE, D. L. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02467-0 · Cited by 21
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: A post Hoc analysis of subpopulations from three pooled clinical trials
Feldman, T., Davidson, M. H., Shah, A. K., Maccubbin, D., Meehan, A. G., Zakson, M., Tribble, D. L., Veltri, E. P., & Mitchel, Y. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.06.001 · Cited by 21
Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery disease
Hoffmeister, A., Rothenbacher, D., Kunze, M., Brenner, H., & Köenig, W. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2004.09.008 · Cited by 21
Effect of the Early Administration of Pravastatin on C-Reactive Protein and Interleukin-6 Levels in the Acute Phase of Myocardial Infarction With ST Segment Elevation
Gonzálvez, M., Ros, J. A. R., Pérez-Paredes, M., Lozano, M. L., Giménez, D. M., Martínez-Corbalán, F., Carnero, A., Cubero, T., Gómez, A. E., & Vicente, V. (2004) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(06)60469-6 · Cited by 20
The Guidelines Battle on Starting Statins
D’Agostino, R. B., Ansell, B. J., Mora, S., & Krumholz, H. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmclde1314766 · Cited by 20
HS‐CRP Modifies the Prognostic Value of Platelet Count for Clinical Outcomes After Ischemic Stroke
Liu, F., Yang, P., Wang, Y., Shi, M., Wang, R., Xu, Q., Peng, Y., Chen, J., Zhang, J., Wang, A., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030007 · Cited by 20
The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion From Human Coronary Artery Endothelial Cells
Haas, M. J., Jurado-Flores, M., Hammoud, R., Feng, V., Gonzales, K., Onstead‐Haas, L., & Mooradian, A. D. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000648 · Cited by 21
Markers of Inflammation and Cardiovascular Disease
Bertoméu, V., & González‐Juanatey, J. R. (2009) · American Journal of Cardiovascular Drugs · doi:10.2165/1153161-s0-000000000-00000 · Cited by 20
Association between hs-CRP Levels and the Outcomes of Patients with Small-Artery Occlusion
Qiu, R., Gao, Y., Hou, D., Wang, Y., Yu, C., Wang, W., Liu, S., Gao, C., Tong, X., & Wu, J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00191 · Cited by 20
Therapy Insight: management of cardiovascular disease in the renal transplant recipient
Rigatto, C., & Parfrey, P. S. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0253 · Cited by 20
Relation of C-Reactive Protein and One-Year Survival After Acute Myocardial Infarction With Versus Without Statin Therapy
Kinjo, K., Sato, H., Sakata, Y., Nakatani, D., Mizuno, H., Shimizu, M., Nishino, M., Ito, H., Tanouchi, J., Nanto, S., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.030 · Cited by 20
The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in patients with unstable angina and non-Q-wave myocadial infarction
Ošťádal, P., Alan, D., Hajek, P., Horak, D., Vejvoda, J., Trefanec, J., Mates, M., & Vojacek, J. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1023499727477 · Cited by 20
Risks and benefits of continued aggressive statin therapy
Gotto, A. M. (2003) · Clinical Cardiology · doi:10.1002/clc.4960261503 · Cited by 20
Self-citation
Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia.
Lee, I., Sheu, W., Lin, S.-Y., Lee, W.-J., Song, Y.-M., & Liu, H.-C. (2002) · Journal of diabetes and its complications · doi:10.1016/s1056-8727(02)00184-8 · Cited by 19
Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel
Beavers, C. J., Pau, A. K., Glidden, D. V., Hyle, E. P., Kuriakose, S., Martin, S. S., McComsey, G. A., Thompson, M., Virani, S. S., & Baker, J. V. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03564 · Cited by 20
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity
Zhang, L., Li, Y., Yang, B., Lu, L., Wang, X., Ge, M., Jing, Q., Ma, Y., Wang, G., Liu, H., et al. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.226064 · Cited by 19
The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis
Zhang, J., Wang, X., Tian, W., Wang, T., Jia, J., Lai, R., Wang, T., Zhang, Z., Song, L., Ju, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.936817 · Cited by 20
Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?
Hingorani, A. D., Sofat, R., Morris, R. W., Whincup, P. H., Lowe, G. D. O., Mindell, J. S., Sattar, N. A., Casas, J. P., & Shah, T. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs168 · Cited by 20
Present and Future Biochemical Markers for Detection of Acute Coronary Syndrome
Eriksson, S., Wittfooth, S., & Pettersson, K. S. I. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600793082 · Cited by 19
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results
Verma, S., Lonn, E., Nanji, A., Browne, K. F., Ward, R., Robertson, A., Conradson, H. E., Hildebrand, K., Brant, R., & Anderson, T. J. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70508-2 · Cited by 19
HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
Bockorny, B., & Dasanu, C. A. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2236-4 · Cited by 19
Moving toward new statin guidelines in a post-JUPITER world: Principles to consider
Ridker, P. M. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0039-1 · Cited by 19
Self-citation
Contemporary Approach to the Diagnosis and Management of Non–ST-Segment Elevation Acute Coronary Syndromes
Boden, W. E., Shah, P. K., Gupta, V., & Ohman, E. M. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.11.003 · Cited by 20
Rationale, design and methods of the CASHMERE study†
Simon, T., Boutouyrie, P., Gompel, A., Christin‐Maître, S., Laurent, S., Thuillez, C., Zannad, F. M., Bernaud, C., Jaillon, P., & on behalf of the CASHMERE investigators (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2003.00233.x · Cited by 19
Effect of Chronic Statin Pretreatment on Hospital Outcome in Patients With Acute Non-ST-Elevation Myocardial Infarction
Bauer, T., Böhm, M., Zahn, R., Jünger, C., Koeth, O., Gitt, A. K., Bestehorn, K. P., Senges, J., & Zeymer, U. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181976a3c · Cited by 19
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Michos, E. D., Narla, V., Blaha, M. J., & Blumenthal, R. S. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6412 · Cited by 19
Associations of Postmenopausal Hormone Therapy with Markers of Hemostasis and Inflammation and Lipid Profiles in Diabetic and Nondiabetic American Indian Women: The Strong Heart Study
Zhang, Y., Howard, B. V., Cowan, L. D., Welty, T. K., Schaefer, C. F., Wild, R. A., Yeh, J. L., & Lee, E. T. (2004) · Journal of Women s Health · doi:10.1089/154099904322966137 · Cited by 19
Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction
Ballantyne, C. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.025 · Cited by 18
The Functional Role of C-Reactive Protein in Aortic Wall Calcification
Warrier, B. K., Mallipeddi, R., Karla, P. K., & Lee, C. (2005) · Cardiology · doi:10.1159/000086686 · Cited by 19
Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease
Frisinghelli, A., & Mafrici, A. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727090-00001 · Cited by 19
Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients
Huang, C. Y., Wu, T.-C., Lin, W., Leu, H., Lin, C., Lin, S.-Y., & Chen, J. W. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01598.x · Cited by 19
Total Serum Cholesterol and Recovery From Disability Among Hospitalized Older Adults
Onder, G., Volpato, S., Liperoti, R., D'Arco, C., Maraldi, C., Fellin, R., Bernabei, R., Landi, F., & on Behalf of the GIFA Investigators (2006) · The Journals of Gerontology Series A · doi:10.1093/gerona/61.7.736 · Cited by 19
Other Medical Therapies
Jacobs, B. S., Castellanos, M., & Madhavan, R. (2004) · Wiley eBooks · doi:10.1002/9780470988442.ch15 · Cited by 19
The Role of C-Reactive Protein in Acute Myocardial Infarction: Unmasking Diagnostic, Prognostic, and Therapeutic Insights
Mitsis, A., Sokratous, S., Karmioti, G., Kyriakou, M., Drakomathioulakis, M., Myrianthefs, M. M., Eftychiou, C., Kadoglou, N. P. E., Tzikas, S., Fragakis, N., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134795 · Cited by 19
Colchicine for Coronary Artery Disease: A Review
Chen, T., Liu, G., & Yu, B. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.892588 · Cited by 18
Exploring the Landscape of Anti-Inflammatory Trials: A Comprehensive Review of Strategies for Targeting Inflammation in Acute Myocardial Infraction
Mitsis, A., Kyriakou, M., Sokratous, S., Karmioti, G., Drakomathioulakis, M., Myrianthefs, M. M., Ziakas, A., Tzikas, S., & Kassimis, G. (2024) · Biomedicines · doi:10.3390/biomedicines12030701 · Cited by 18
JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
Shishehbor, M. H., & Hazen, S. L. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75a.08105 · Cited by 19
Atherosclerosis, inflammation, leukocyte function and the effect of statins
Meyer-Sabellek, W. A., & Brasch, H. (2006) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280113648 · Cited by 18
Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women
Jiménez, M. C., Rexrode, K. M., Kotler, G., Everett, B. M., Glynn, R. J., Lee, I.-M. M., Buring, J. E., Ridker, P. M., & Sesso, H. D. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw050 · Cited by 18
Self-citation
Population Impact & Efficiency of Benefit‐Targeted Versus Risk‐Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease
Pletcher, M. J., Pignone, M. P., Jarmul, J. A., Moran, A. E., Vittinghoff, E., & Newman, T. B. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004316 · Cited by 18
Targeted HFpEF therapy based on matchmaking of human and animal models
Aizpurua, A. B., Schroen, B. L. M., van Bilsen, M., & van Empel, V. P. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00024.2018 · Cited by 20
Cardiovascular Disorders
Hamilton, D. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-68164-1_16 · Cited by 18
Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease
Shibasaki, M., Wang, J.-G., de Figueiredo, J. L., New, S. E. P., Quillard, T., Goettsch, C., Koga, J., Sonoki, H., Matsumoto, J., Aikawa, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138047 · Cited by 18
Rosuvastatin
Carter, N. J. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11204600-000000000-00000 · Cited by 18
Usefulness of Cardiac Biomarker Score for Risk Stratification in Stable Patients Undergoing Elective Cardiac Evaluation Across Glycemic Status
Tang, W. H. W., Iqbal, N. S., Wu, Y., & Hazen, S. L. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.10.027 · Cited by 18
Factors determining high‐sensitivity C‐reactive protein values in the Spanish population. Di@bet.es study
Rojo‐Martínez, G., Soriguer, F., Colomo, N., CALLE, A. L., Goday, A., Bordiú, E., Delgado, E., Torre, E. L. M., Ortega, E., Urrutia, I., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/eci.12002 · Cited by 19
Statin Therapy for Cardiac Hypertrophy and Heart Failure
Liao, J. K. (2004) · Journal of Investigative Medicine · doi:10.1177/108155890405200433 · Cited by 22
Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection
Kent, S. M., & Taylor, A. J. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.07.040 · Cited by 18
Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia
Isma, N., Barani, J., Mattiasson, I., Lindblad, B., & Gottsäter, A. (2008) · Angiology · doi:10.1177/0003319707306144 · Cited by 18
The role of inflammation and infection in coronary artery disease: a clinical perspective
McKechnie, R. S., & Rubenfire, M. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00531-1 · Cited by 18
Effects of lipids on thrombotic mechanisms in atherosclerosis
Tousoulis, D., Davies, G., Ambrose, J. A., Tentolouris, C. A., Stefanadis, C., & Toutouzas, P. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00300-5 · Cited by 18
C-reactive protein and prognosis after percutaneous coronary intervention
Blake, G. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3130 · Cited by 18
Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease
Balk, E. M., Lau, J., Goudas, L. C., Jordan, H. S., Kupelnick, B., Kim, L. U., & Karas, R. H. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00011 · Cited by 187
Identification of Inflamed Atherosclerotic Lesions In Vivo Using PET-CT
Jezovnik, M. K., Zidar, N., Ležaić, L., Geršak, B., & Poredoš, P. (2013) · Inflammation · doi:10.1007/s10753-013-9755-3 · Cited by 17
Critical Review of High-Sensitivity C-Reactive Protein and Coronary Artery Calcium for the Guidance of Statin Allocation
Kim, J., McEvoy, J. W., Nasir, K., Budoff, M. J., Arad, Y., Blumenthal, R. S., & Blaha, M. J. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000519 · Cited by 17
A Review of Perioperative Statin Therapy for Noncardiac Surgery
Skrlin, S. M., & Hou, V. W. (2010) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253210386387 · Cited by 17
The Effect of Aspirin on C-Reactive Protein in Hypertensive Patients
Kim, M., Kim, C. J., Seo, J., Chung, W.-Y., Kim, S., Zo, J., Rho, E. Y., Shin, S., & Yoon, J. H. (2010) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2010.503302 · Cited by 17
Atorvastatin as adjunctive therapy for chronic plaque type psoriasis versus betamethasone valerate alone: A randomized, double-blind, placebo-controlled trial
Chua, S. H., Tioleco-Ver, G. M. S., Dayrit-Castro, C. A. F., Mojica, W. P., Dofitas, B. L., & Frez, M. L. F. (2017) · Indian Journal of Dermatology Venereology and Leprology · doi:10.4103/ijdvl.ijdvl_425_16 · Cited by 17
Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis
Berns, J. S., & Mosenkis, A. (2005) · Hemodialysis International · doi:10.1111/j.1492-7535.2005.01113.x · Cited by 17
Interaction between simvastatin and metoprolol with respect to cardiac β-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients
Nette, A. F., Abraham, G., Ungemach, F. R., Oertel, R., Kirch, W., Leineweber, K., Mohr, F., & Dhein, S. (2005) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-005-0005-6 · Cited by 17
Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients
Sindhu, S., Singh, H. K., Salman, M. T., Fatima, J., & Verma, V. K. (2011) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.85954 · Cited by 17
Potential Roles for Statins in Critically Ill Patients
Weant, K. A., & Cook, A. M. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.9.1279 · Cited by 17
C-Reactive Protein Predicts Death in Patients with Non-Ischemic Cardiomyopathy
Ronnow, B. S., Reyna, S. P., Muhlestein, J. B., Horne, B. D., Maycock, C. A. A., Bair, T. L., Carlquist, J. F., Kfoury, A. G., Anderson, J. L., & Renlund, D. G. (2005) · Cardiology · doi:10.1159/000088138 · Cited by 17
Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?
Fabbri, G., & Maggioni, A. P. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0025-6 · Cited by 19
Role of adhesion molecules in the induction of restenosis after angioplasty in the lower limb
Heider, P., Wildgruber, M., Weiss, W., Berger, H., Henning, E. H., & Wolf, O. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.11.061 · Cited by 17
Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins.
Nash, D. T. (2005) · PubMed Central · Cited by 17
Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease
Pulido, J. S., McConnell, J. P., Peterson, L. M., Highsmith, W. E., Lennon, R. J., Bryant, S. C., Berger, P. B., & Somers, V. K. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61026-4 · Cited by 16
Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
OLSSON, A. G., Schwartz, G. G., Jonasson, L., & Linderfalk, C. (2002) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2002.01017.x · Cited by 17
Coronary Artery Disease Prognosis and C-Reactive Protein Levels Improve in Proportion to Percent Lowering of Low-Density Lipoprotein
O’Keefe, J. H., Cordain, L., Jones, P. G., & Abuissa, H. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.062 · Cited by 17
The Complex Mechanisms and the Potential Effects of Statins on Vascular Calcification: A Narrative Review
Kadoglou, N. P. E., Stasinopoulou, M., Velidakis, N., Khattab, E., Christodoulou, E., Gkougkoudi, E., & Valsami, G. N. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2502051 · Cited by 18
Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications
Perone, F., Bernardi, M., Spadafora, L., Betti, M., Cacciatore, S., Saia, F., Fogacci, F., Jaiswal, V., Asher, E., Paneni, F., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12050171 · Cited by 19
Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial
Hepprich, M., Mudry, J. M., Gregoriano, C., Jornayvaz, F. R., Carballo, S., Wojtusciszyn, A., Bart, P., Chiche, J., Fischli, S., Baumgartner, T., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101649 · Cited by 16
Statins Modulate Microenvironmental Cues Driving Macrophage Polarization in Simulated Periodontal Inflammation
Alkakhan, W., Farrar, N., Sikora, V., Emecen‐Huja, P., Huja, S. S., Yilmaz, Ö., & Pandruvada, S. N. M. (2023) · Cells · doi:10.3390/cells12151961 · Cited by 16

Authors: Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
Affiliations: Brigham and Women's Hospital (US)
University of North Texas Health Science Center (US)
Wilford Hall Ambulatory Surgical Center (US)
ORCID: Ridker, Paul M.
Rifai, Nader
Weis, Stephen E.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-06-28
Volume: 344
Issue: 26
Pages: 1959-1965
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200106283442601
OpenAlex: W2316243284
Cited by: 1,557
References: 27
Citations by year: 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
FWCI: 158.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Doris Duke Charitable Foundation
American Heart Association
Fondation Leducq
National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
MeSH terms: Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks